A novel prostate cancer treatment-;225Ac-PSMA-617 radioligand therapy-;has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients, according to research published by The Journal of Nuclear Medicine.
Novel radioligand therapy shown to increase survival of metastatic prostate cancer patients
A novel prostate cancer treatment-;225Ac-PSMA-617 radioligand therapy-;has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients, according to research published by The Journal of Nuclear Medicine.